Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec
BackgroundVoretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.MethodsSeven eyes of five patients (14, 21, 23, 24, 36 years, 1 ma...
Gespeichert in:
Veröffentlicht in: | British journal of ophthalmology 2022-06, Vol.106 (6), p.831-838 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 838 |
---|---|
container_issue | 6 |
container_start_page | 831 |
container_title | British journal of ophthalmology |
container_volume | 106 |
creator | Stingl, Krunoslav Kempf, Melanie Bartz-Schmidt, Karl U Dimopoulos, Spyridon Reichel, Felix Jung, Ronja Kelbsch, Carina Kohl, Susanne Kortüm, Friederike Charlotte Nasser, Fadi Peters, Tobias Wilhelm, Barbara Wissinger, Bernd Wozar, Fabian Zrenner, Eberhart Fischer, M Dominik Stingl, Katarina |
description | BackgroundVoretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.MethodsSeven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic RPE65 mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.ResultsAll except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R2>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R2=0.5).ConclusionsThe presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function. |
doi_str_mv | 10.1136/bjophthalmol-2020-318286 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9132865</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2479747720</sourcerecordid><originalsourceid>FETCH-LOGICAL-b537t-82afe7d8e006704a9a039c861f6c659c05eea1aa091575f994579974a10c9103</originalsourceid><addsrcrecordid>eNqVUU2LFDEQDaK44-pfkIAXL6356E46F0EWv2DBg3sPNZnq7QzdSZukR_bfm2HWcfUinopKvffqVR4hlLM3nEv1druPy1hGmOY4NYIJ1kjei149Ihveqr4-afOYbBhjuuFc8QvyLOd9bYXi-im5kLLVQiuzIcu3BYqHiULY0YLzElNtEuY4rcXHQONAy4h0GWOJCR0uteQjwK1Id3cBZu8yhaFgoiUhlBlDoT98GemhEoq_xYA04ALpEA_onpMnA0wZX9zXS3Lz8cPN1efm-uunL1fvr5ttJ3VpegED6l2PjCnNWjDApHG94oNyqjOOdYjAAZjhne4GY9pOG6Nb4MwZzuQleXeSXdbtjDtXTdXD7JL8DOnORvD2z0nwo72NB2u4rB_ZVYHX9wIpfl8xFzv77HCaIGBcsxWtruu0Fsddr_6C7uOaQr3OCqW0aFkn-4rqTyiXYs4Jh7MZzuwxVfswVXtM1Z5SrdSXD485E3_FWAHyBNjO-_-RbX-zzpb_SfsJ4pPG7g</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2667240538</pqid></control><display><type>article</type><title>Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec</title><source>MEDLINE</source><source>PubMed Central</source><creator>Stingl, Krunoslav ; Kempf, Melanie ; Bartz-Schmidt, Karl U ; Dimopoulos, Spyridon ; Reichel, Felix ; Jung, Ronja ; Kelbsch, Carina ; Kohl, Susanne ; Kortüm, Friederike Charlotte ; Nasser, Fadi ; Peters, Tobias ; Wilhelm, Barbara ; Wissinger, Bernd ; Wozar, Fabian ; Zrenner, Eberhart ; Fischer, M Dominik ; Stingl, Katarina</creator><creatorcontrib>Stingl, Krunoslav ; Kempf, Melanie ; Bartz-Schmidt, Karl U ; Dimopoulos, Spyridon ; Reichel, Felix ; Jung, Ronja ; Kelbsch, Carina ; Kohl, Susanne ; Kortüm, Friederike Charlotte ; Nasser, Fadi ; Peters, Tobias ; Wilhelm, Barbara ; Wissinger, Bernd ; Wozar, Fabian ; Zrenner, Eberhart ; Fischer, M Dominik ; Stingl, Katarina</creatorcontrib><description>BackgroundVoretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.MethodsSeven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic RPE65 mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.ResultsAll except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R2>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R2=0.5).ConclusionsThe presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.</description><identifier>ISSN: 0007-1161</identifier><identifier>EISSN: 1468-2079</identifier><identifier>DOI: 10.1136/bjophthalmol-2020-318286</identifier><identifier>PMID: 33472769</identifier><language>eng</language><publisher>BMA House, Tavistock Square, London, WC1H 9JR: BMJ Publishing Group Ltd</publisher><subject>Clinical Science ; diagnostic tests/investigation ; dystrophy ; FDA approval ; Female ; Females ; genetics ; Humans ; Male ; Medical diagnosis ; Mutation ; Ophthalmology ; Photoreceptors ; Retina ; Retinal Dystrophies - genetics ; Surgery ; Tomography ; Tomography, Optical Coherence ; treatment other ; Visual Acuity ; Visual Field Tests</subject><ispartof>British journal of ophthalmology, 2022-06, Vol.106 (6), p.831-838</ispartof><rights>Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.</rights><rights>Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</rights><rights>2022 Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/ . Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b537t-82afe7d8e006704a9a039c861f6c659c05eea1aa091575f994579974a10c9103</citedby><cites>FETCH-LOGICAL-b537t-82afe7d8e006704a9a039c861f6c659c05eea1aa091575f994579974a10c9103</cites><orcidid>0000-0001-9817-2860 ; 0000-0002-0370-0462 ; 0000-0002-5309-7155 ; 0000-0002-5611-2672 ; 0000-0003-2846-9663 ; 0000-0001-8547-7593 ; 0000-0002-8132-911X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132865/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9132865/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27903,27904,53769,53771</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33472769$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Stingl, Krunoslav</creatorcontrib><creatorcontrib>Kempf, Melanie</creatorcontrib><creatorcontrib>Bartz-Schmidt, Karl U</creatorcontrib><creatorcontrib>Dimopoulos, Spyridon</creatorcontrib><creatorcontrib>Reichel, Felix</creatorcontrib><creatorcontrib>Jung, Ronja</creatorcontrib><creatorcontrib>Kelbsch, Carina</creatorcontrib><creatorcontrib>Kohl, Susanne</creatorcontrib><creatorcontrib>Kortüm, Friederike Charlotte</creatorcontrib><creatorcontrib>Nasser, Fadi</creatorcontrib><creatorcontrib>Peters, Tobias</creatorcontrib><creatorcontrib>Wilhelm, Barbara</creatorcontrib><creatorcontrib>Wissinger, Bernd</creatorcontrib><creatorcontrib>Wozar, Fabian</creatorcontrib><creatorcontrib>Zrenner, Eberhart</creatorcontrib><creatorcontrib>Fischer, M Dominik</creatorcontrib><creatorcontrib>Stingl, Katarina</creatorcontrib><title>Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec</title><title>British journal of ophthalmology</title><addtitle>Br J Ophthalmol</addtitle><addtitle>Br J Ophthalmol</addtitle><description>BackgroundVoretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.MethodsSeven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic RPE65 mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.ResultsAll except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R2>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R2=0.5).ConclusionsThe presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.</description><subject>Clinical Science</subject><subject>diagnostic tests/investigation</subject><subject>dystrophy</subject><subject>FDA approval</subject><subject>Female</subject><subject>Females</subject><subject>genetics</subject><subject>Humans</subject><subject>Male</subject><subject>Medical diagnosis</subject><subject>Mutation</subject><subject>Ophthalmology</subject><subject>Photoreceptors</subject><subject>Retina</subject><subject>Retinal Dystrophies - genetics</subject><subject>Surgery</subject><subject>Tomography</subject><subject>Tomography, Optical Coherence</subject><subject>treatment other</subject><subject>Visual Acuity</subject><subject>Visual Field Tests</subject><issn>0007-1161</issn><issn>1468-2079</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>9YT</sourceid><sourceid>ACMMV</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqVUU2LFDEQDaK44-pfkIAXL6356E46F0EWv2DBg3sPNZnq7QzdSZukR_bfm2HWcfUinopKvffqVR4hlLM3nEv1druPy1hGmOY4NYIJ1kjei149Ihveqr4-afOYbBhjuuFc8QvyLOd9bYXi-im5kLLVQiuzIcu3BYqHiULY0YLzElNtEuY4rcXHQONAy4h0GWOJCR0uteQjwK1Id3cBZu8yhaFgoiUhlBlDoT98GemhEoq_xYA04ALpEA_onpMnA0wZX9zXS3Lz8cPN1efm-uunL1fvr5ttJ3VpegED6l2PjCnNWjDApHG94oNyqjOOdYjAAZjhne4GY9pOG6Nb4MwZzuQleXeSXdbtjDtXTdXD7JL8DOnORvD2z0nwo72NB2u4rB_ZVYHX9wIpfl8xFzv77HCaIGBcsxWtruu0Fsddr_6C7uOaQr3OCqW0aFkn-4rqTyiXYs4Jh7MZzuwxVfswVXtM1Z5SrdSXD485E3_FWAHyBNjO-_-RbX-zzpb_SfsJ4pPG7g</recordid><startdate>20220601</startdate><enddate>20220601</enddate><creator>Stingl, Krunoslav</creator><creator>Kempf, Melanie</creator><creator>Bartz-Schmidt, Karl U</creator><creator>Dimopoulos, Spyridon</creator><creator>Reichel, Felix</creator><creator>Jung, Ronja</creator><creator>Kelbsch, Carina</creator><creator>Kohl, Susanne</creator><creator>Kortüm, Friederike Charlotte</creator><creator>Nasser, Fadi</creator><creator>Peters, Tobias</creator><creator>Wilhelm, Barbara</creator><creator>Wissinger, Bernd</creator><creator>Wozar, Fabian</creator><creator>Zrenner, Eberhart</creator><creator>Fischer, M Dominik</creator><creator>Stingl, Katarina</creator><general>BMJ Publishing Group Ltd</general><general>BMJ Publishing Group LTD</general><general>BMJ Publishing Group</general><scope>9YT</scope><scope>ACMMV</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9817-2860</orcidid><orcidid>https://orcid.org/0000-0002-0370-0462</orcidid><orcidid>https://orcid.org/0000-0002-5309-7155</orcidid><orcidid>https://orcid.org/0000-0002-5611-2672</orcidid><orcidid>https://orcid.org/0000-0003-2846-9663</orcidid><orcidid>https://orcid.org/0000-0001-8547-7593</orcidid><orcidid>https://orcid.org/0000-0002-8132-911X</orcidid></search><sort><creationdate>20220601</creationdate><title>Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec</title><author>Stingl, Krunoslav ; Kempf, Melanie ; Bartz-Schmidt, Karl U ; Dimopoulos, Spyridon ; Reichel, Felix ; Jung, Ronja ; Kelbsch, Carina ; Kohl, Susanne ; Kortüm, Friederike Charlotte ; Nasser, Fadi ; Peters, Tobias ; Wilhelm, Barbara ; Wissinger, Bernd ; Wozar, Fabian ; Zrenner, Eberhart ; Fischer, M Dominik ; Stingl, Katarina</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b537t-82afe7d8e006704a9a039c861f6c659c05eea1aa091575f994579974a10c9103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Clinical Science</topic><topic>diagnostic tests/investigation</topic><topic>dystrophy</topic><topic>FDA approval</topic><topic>Female</topic><topic>Females</topic><topic>genetics</topic><topic>Humans</topic><topic>Male</topic><topic>Medical diagnosis</topic><topic>Mutation</topic><topic>Ophthalmology</topic><topic>Photoreceptors</topic><topic>Retina</topic><topic>Retinal Dystrophies - genetics</topic><topic>Surgery</topic><topic>Tomography</topic><topic>Tomography, Optical Coherence</topic><topic>treatment other</topic><topic>Visual Acuity</topic><topic>Visual Field Tests</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Stingl, Krunoslav</creatorcontrib><creatorcontrib>Kempf, Melanie</creatorcontrib><creatorcontrib>Bartz-Schmidt, Karl U</creatorcontrib><creatorcontrib>Dimopoulos, Spyridon</creatorcontrib><creatorcontrib>Reichel, Felix</creatorcontrib><creatorcontrib>Jung, Ronja</creatorcontrib><creatorcontrib>Kelbsch, Carina</creatorcontrib><creatorcontrib>Kohl, Susanne</creatorcontrib><creatorcontrib>Kortüm, Friederike Charlotte</creatorcontrib><creatorcontrib>Nasser, Fadi</creatorcontrib><creatorcontrib>Peters, Tobias</creatorcontrib><creatorcontrib>Wilhelm, Barbara</creatorcontrib><creatorcontrib>Wissinger, Bernd</creatorcontrib><creatorcontrib>Wozar, Fabian</creatorcontrib><creatorcontrib>Zrenner, Eberhart</creatorcontrib><creatorcontrib>Fischer, M Dominik</creatorcontrib><creatorcontrib>Stingl, Katarina</creatorcontrib><collection>BMJ Open Access Journals</collection><collection>BMJ Journals:Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Stingl, Krunoslav</au><au>Kempf, Melanie</au><au>Bartz-Schmidt, Karl U</au><au>Dimopoulos, Spyridon</au><au>Reichel, Felix</au><au>Jung, Ronja</au><au>Kelbsch, Carina</au><au>Kohl, Susanne</au><au>Kortüm, Friederike Charlotte</au><au>Nasser, Fadi</au><au>Peters, Tobias</au><au>Wilhelm, Barbara</au><au>Wissinger, Bernd</au><au>Wozar, Fabian</au><au>Zrenner, Eberhart</au><au>Fischer, M Dominik</au><au>Stingl, Katarina</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec</atitle><jtitle>British journal of ophthalmology</jtitle><stitle>Br J Ophthalmol</stitle><addtitle>Br J Ophthalmol</addtitle><date>2022-06-01</date><risdate>2022</risdate><volume>106</volume><issue>6</issue><spage>831</spage><epage>838</epage><pages>831-838</pages><issn>0007-1161</issn><eissn>1468-2079</eissn><abstract>BackgroundVoretigene neparvovec is a gene therapeutic agent for treatment of retinal dystrophies caused by bi-allelic RPE65 mutations. In this study, we report on a novel and objective evaluation of a retinotopic photoreceptor rescue.MethodsSeven eyes of five patients (14, 21, 23, 24, 36 years, 1 male, 4 females) with bi-allelic RPE65 mutations have been treated with voretigene neparvovec. The clinical examinations included visual acuity testing, dark-adapted full-field stimulus threshold (FST), dark-adapted chromatic perimeter (DAC) with a 30-degree grid, and a 30 degrees grid scotopic and photopic chromatic pupil campimetry (CPC). All evaluations and spectral domain optical coherence tomography were performed at baseline, 1 month and 3 months.ResultsAll except the oldest patient had a measurable improvement of the rod function assessed via FST, DAC or scotopic CPC at 1 month. The visual acuity improved slightly or remained stable in all eyes. A cone function improvement as measured by photopic CPC was observed in three eyes. The gain of the dark-adapted threshold with blue FST and the DAC stimuli (cyan) average correlated strongly with age (R2>0.7). The pupil response improvement in the scotopic CPC correlated with the baseline local retinal volume (R2=0.5).ConclusionsThe presented protocols allow evaluating the individual spatial and temporal effects of gene therapy effects. Additionally, we explored parameters that correlated with the success of the therapy. CPC and DAC present new and fast ways to assess functional changes in retinotopic maps of rod and cone function, measuring complementary aspects of retinal function.</abstract><cop>BMA House, Tavistock Square, London, WC1H 9JR</cop><pub>BMJ Publishing Group Ltd</pub><pmid>33472769</pmid><doi>10.1136/bjophthalmol-2020-318286</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0001-9817-2860</orcidid><orcidid>https://orcid.org/0000-0002-0370-0462</orcidid><orcidid>https://orcid.org/0000-0002-5309-7155</orcidid><orcidid>https://orcid.org/0000-0002-5611-2672</orcidid><orcidid>https://orcid.org/0000-0003-2846-9663</orcidid><orcidid>https://orcid.org/0000-0001-8547-7593</orcidid><orcidid>https://orcid.org/0000-0002-8132-911X</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0007-1161 |
ispartof | British journal of ophthalmology, 2022-06, Vol.106 (6), p.831-838 |
issn | 0007-1161 1468-2079 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9132865 |
source | MEDLINE; PubMed Central |
subjects | Clinical Science diagnostic tests/investigation dystrophy FDA approval Female Females genetics Humans Male Medical diagnosis Mutation Ophthalmology Photoreceptors Retina Retinal Dystrophies - genetics Surgery Tomography Tomography, Optical Coherence treatment other Visual Acuity Visual Field Tests |
title | Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T20%3A07%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Spatial%20and%20temporal%20resolution%20of%20the%20photoreceptors%20rescue%20dynamics%20after%20treatment%20with%20voretigene%20neparvovec&rft.jtitle=British%20journal%20of%20ophthalmology&rft.au=Stingl,%20Krunoslav&rft.date=2022-06-01&rft.volume=106&rft.issue=6&rft.spage=831&rft.epage=838&rft.pages=831-838&rft.issn=0007-1161&rft.eissn=1468-2079&rft_id=info:doi/10.1136/bjophthalmol-2020-318286&rft_dat=%3Cproquest_pubme%3E2479747720%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2667240538&rft_id=info:pmid/33472769&rfr_iscdi=true |